title: [Prophylaxis of cytomegalovirus infection in liver transplantation].
abstract: CMV prevention strategies in liver transplant recipients should be stratified according to serological status. In donor (D)-/recipient (R)- combinations, no prophylaxis or preemptive therapy is recommended. In the remaining combinations, the most widely used strategies are universal prophylaxis and preemptive therapy. Both strategies are effective compared with placebo but have not been compared with each other in well-designed clinical trials. Preemptive therapy is the preferred strategy in low-risk patients while prophylaxis is the most widely used option in those at high-risk. Delayed CMV disease is an adverse consequence of universal prophylaxis. Prolongation of prophylaxis from 100 to 200 days does not reduce the incidence of CMV disease. CMV-specific cell mediated immunity, facilitated by preemptive therapy and delayed by prophylaxis, has a therapeutic effect by reducing CMV replication. The drug of choice in both strategies is valganciclovir but the duration and dose differ. When preemptive therapy is used, viremia monitoring is required for the first 4 months. The technique of choice is quantitative polymerase chain reaction. Given the lack of conclusive data, the choice of one or other strategy in these patients should be individualized in each patient and center according to the available resources and possibilities of follow-up.
authors.affiliation: Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Virgen del Rocío/IBIS, Sevilla, España. jmcisnerosh@gmail.com
authors.forename: José Miguel
authors.initials: JM
authors.lastname: Cisneros
authors.forename: Evaristo
authors.initials: E
authors.lastname: Varo
mesh_terms: D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D006801:Humans; D016031:Liver Transplantation; D011183:Postoperative Complications / Q000517:prevention & control*; D017410:Practice Guidelines as Topic